CHARACTERISTICS OF GRAVES' OPHTHALMOPATHY ASSESSED BY CLINICAL ACTIVITY SCORE (CAS) AND ASSOCIATED FACTORS AT THE NATIONAL HOSPITAL OF ENDOCRINOLOGY

Gia Nam Đỗ, Thị Phương Thúy Nguyễn, Hữu Thành Lê

Main Article Content

Abstract

Objectives: To describe the characteristics of Graves' orbitopathy and identify associated factors at the National Hospital of Endocrinology. Subjects and Methods: A cross-sectional descriptive study was conducted on 74 patients diagnosed with Graves' orbitopathy presenting for examination and treatment at the National Hospital of Endocrinology from February 2025 to October 2025. Study variables included: age, gender, tobacco exposure, goiter characteristics, FT4, TSH, and TRAb levels, NOSPECS classification, and Clinical Activity Score (CAS). Results: The majority of patients (86.5%) presented with inactive orbitopathy (CAS < 3), while 13.5% were in the active stage (CAS ≥ 3). The most common clinical signs according to the CAS scale were eyelid edema (59.5%) and conjunctival injection (24.3%). Analysis of associated factors indicated that male gender (OR=13.6; 95% CI: 2.44-75.4) and exposure to tobacco smoke (OR=4.45; 95% CI: 1.05-18.94) were independent risk factors for active orbitopathy. No statistically significant association was found between age, disease duration, goiter characteristics, TRAb levels, or thyroid function and the CAS score. Conclusion: The prevalence of active Graves' orbitopathy was 13.5%. Routine application of the CAS score during clinical examination is recommended, along with enhanced smoking cessation counseling for both patients and their families

Article Details

References

Tanda M, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center. The Journal of Clinical Endocrinology & Metabolism. 2013;98(4):1443-1449.
2. Bahn R. Current insights into the pathogenesis of Graves’ ophthalmopathy. Hormone and Metabolic Research. 2015;47(10):773-778.
3. Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. European Journal of Endocrinology. 2021;185(4): G43-G67.
4. Mourits M, Koornneef L, Wiersinga W, et al. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. British Journal of Ophthalmology. 1989;73(8):639-644.
5. Vestergaard P. Smoking and thyroid disorders–a meta-analysis European Journal of Endocrinology 2002;146(2):153-161.